Karyotypic change between diagnosis and relapse as a predictor of salvage therapy outcome in AML patients

Yundeok Kim, Jieun Jang, Shin Yong Hyun, Dohyu Hwang, Soo Jeong Kim, Jin Seok Kim, Jun Won Cheong, Yoo Hong Min

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: Only a few patients who experience AML relapse derive lasting benefit from re-induction therapy. The utility of reassessing the disease karyotype at relapse is unclear. The main goals of this study were to identify prognostic factors for AML relapse and to determine the prognostic utility of karyotypic change between diagnosis and relapse as a variable for predicting response to salvage therapy for relapsed AML.Methods: This retrospective study included 58 patients with relapsed AML treated at the Yonsei University College of Medicine between 2005 and 2010. Karyotypes at both diagnosis and relapse were available for 45 patients (77%). A change in karyotype at relapse was observed in 17 of 45 cases (37%), and no change was noted in 28 of 45 cases (62%) Results: Karyotypic changes between diagnosis and relapse were associated with the response rate (RR) to salvage therapy (P=0.016). Overall survival (OS) and event-free survival (EFS) in the group with karyotypic changes between diagnosis and relapse were significantly different from those with no karyotypic changes (P=0.004 and P=0.010, respectively). We applied multiple multivariate Cox regression analyses to identify independent prognostic factors for overall response (OR), OS, and EFS. A change in karyotype between diagnosis and relapse was significantly associated with OS (P=0.023; RR=2.655) and EFS (P=0.033; RR=2.831) Conclusion: Karyotypic changes between the diagnosis and relapse of AML could be used to predict outcomes and tailor clinical and biological therapeutic strategies for relapsed AML patients.

Original languageEnglish
Pages (from-to)24-30
Number of pages7
JournalBlood Research
Volume48
Issue number1
DOIs
Publication statusPublished - 2013 Dec 24

Fingerprint

Salvage Therapy
Recurrence
Karyotype
Disease-Free Survival
Survival
Retrospective Studies
Regression Analysis
Medicine

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Kim, Yundeok ; Jang, Jieun ; Hyun, Shin Yong ; Hwang, Dohyu ; Kim, Soo Jeong ; Kim, Jin Seok ; Cheong, Jun Won ; Min, Yoo Hong. / Karyotypic change between diagnosis and relapse as a predictor of salvage therapy outcome in AML patients. In: Blood Research. 2013 ; Vol. 48, No. 1. pp. 24-30.
@article{43302a5b0f8845778ede1c318220c1ca,
title = "Karyotypic change between diagnosis and relapse as a predictor of salvage therapy outcome in AML patients",
abstract = "Background: Only a few patients who experience AML relapse derive lasting benefit from re-induction therapy. The utility of reassessing the disease karyotype at relapse is unclear. The main goals of this study were to identify prognostic factors for AML relapse and to determine the prognostic utility of karyotypic change between diagnosis and relapse as a variable for predicting response to salvage therapy for relapsed AML.Methods: This retrospective study included 58 patients with relapsed AML treated at the Yonsei University College of Medicine between 2005 and 2010. Karyotypes at both diagnosis and relapse were available for 45 patients (77{\%}). A change in karyotype at relapse was observed in 17 of 45 cases (37{\%}), and no change was noted in 28 of 45 cases (62{\%}) Results: Karyotypic changes between diagnosis and relapse were associated with the response rate (RR) to salvage therapy (P=0.016). Overall survival (OS) and event-free survival (EFS) in the group with karyotypic changes between diagnosis and relapse were significantly different from those with no karyotypic changes (P=0.004 and P=0.010, respectively). We applied multiple multivariate Cox regression analyses to identify independent prognostic factors for overall response (OR), OS, and EFS. A change in karyotype between diagnosis and relapse was significantly associated with OS (P=0.023; RR=2.655) and EFS (P=0.033; RR=2.831) Conclusion: Karyotypic changes between the diagnosis and relapse of AML could be used to predict outcomes and tailor clinical and biological therapeutic strategies for relapsed AML patients.",
author = "Yundeok Kim and Jieun Jang and Hyun, {Shin Yong} and Dohyu Hwang and Kim, {Soo Jeong} and Kim, {Jin Seok} and Cheong, {Jun Won} and Min, {Yoo Hong}",
year = "2013",
month = "12",
day = "24",
doi = "10.5045/br.2013.48.1.24",
language = "English",
volume = "48",
pages = "24--30",
journal = "Blood Research",
issn = "2287-979X",
publisher = "Korean Society of Hematology",
number = "1",

}

Karyotypic change between diagnosis and relapse as a predictor of salvage therapy outcome in AML patients. / Kim, Yundeok; Jang, Jieun; Hyun, Shin Yong; Hwang, Dohyu; Kim, Soo Jeong; Kim, Jin Seok; Cheong, Jun Won; Min, Yoo Hong.

In: Blood Research, Vol. 48, No. 1, 24.12.2013, p. 24-30.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Karyotypic change between diagnosis and relapse as a predictor of salvage therapy outcome in AML patients

AU - Kim, Yundeok

AU - Jang, Jieun

AU - Hyun, Shin Yong

AU - Hwang, Dohyu

AU - Kim, Soo Jeong

AU - Kim, Jin Seok

AU - Cheong, Jun Won

AU - Min, Yoo Hong

PY - 2013/12/24

Y1 - 2013/12/24

N2 - Background: Only a few patients who experience AML relapse derive lasting benefit from re-induction therapy. The utility of reassessing the disease karyotype at relapse is unclear. The main goals of this study were to identify prognostic factors for AML relapse and to determine the prognostic utility of karyotypic change between diagnosis and relapse as a variable for predicting response to salvage therapy for relapsed AML.Methods: This retrospective study included 58 patients with relapsed AML treated at the Yonsei University College of Medicine between 2005 and 2010. Karyotypes at both diagnosis and relapse were available for 45 patients (77%). A change in karyotype at relapse was observed in 17 of 45 cases (37%), and no change was noted in 28 of 45 cases (62%) Results: Karyotypic changes between diagnosis and relapse were associated with the response rate (RR) to salvage therapy (P=0.016). Overall survival (OS) and event-free survival (EFS) in the group with karyotypic changes between diagnosis and relapse were significantly different from those with no karyotypic changes (P=0.004 and P=0.010, respectively). We applied multiple multivariate Cox regression analyses to identify independent prognostic factors for overall response (OR), OS, and EFS. A change in karyotype between diagnosis and relapse was significantly associated with OS (P=0.023; RR=2.655) and EFS (P=0.033; RR=2.831) Conclusion: Karyotypic changes between the diagnosis and relapse of AML could be used to predict outcomes and tailor clinical and biological therapeutic strategies for relapsed AML patients.

AB - Background: Only a few patients who experience AML relapse derive lasting benefit from re-induction therapy. The utility of reassessing the disease karyotype at relapse is unclear. The main goals of this study were to identify prognostic factors for AML relapse and to determine the prognostic utility of karyotypic change between diagnosis and relapse as a variable for predicting response to salvage therapy for relapsed AML.Methods: This retrospective study included 58 patients with relapsed AML treated at the Yonsei University College of Medicine between 2005 and 2010. Karyotypes at both diagnosis and relapse were available for 45 patients (77%). A change in karyotype at relapse was observed in 17 of 45 cases (37%), and no change was noted in 28 of 45 cases (62%) Results: Karyotypic changes between diagnosis and relapse were associated with the response rate (RR) to salvage therapy (P=0.016). Overall survival (OS) and event-free survival (EFS) in the group with karyotypic changes between diagnosis and relapse were significantly different from those with no karyotypic changes (P=0.004 and P=0.010, respectively). We applied multiple multivariate Cox regression analyses to identify independent prognostic factors for overall response (OR), OS, and EFS. A change in karyotype between diagnosis and relapse was significantly associated with OS (P=0.023; RR=2.655) and EFS (P=0.033; RR=2.831) Conclusion: Karyotypic changes between the diagnosis and relapse of AML could be used to predict outcomes and tailor clinical and biological therapeutic strategies for relapsed AML patients.

UR - http://www.scopus.com/inward/record.url?scp=84890691605&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890691605&partnerID=8YFLogxK

U2 - 10.5045/br.2013.48.1.24

DO - 10.5045/br.2013.48.1.24

M3 - Article

AN - SCOPUS:84890691605

VL - 48

SP - 24

EP - 30

JO - Blood Research

JF - Blood Research

SN - 2287-979X

IS - 1

ER -